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After several decades of research, we now have evidence that at least six interventions
are suitable for immediate use in contemporary clinical practice within high-resource set-
tings and can be expected to safely reduce the rate of preterm birth. These interventions
involve strategies to prevent non-medically indicated late preterm birth; use of maternal
progesterone supplementation; surgical closure of the cervix with cerclage; prevention
of exposure of pregnant women to cigarette smoke; judicious use of fertility treatments;
and dedicated preterm birth prevention clinics. Quantification of the extent of success
is difficult to predict and will be dependent on other clinical, cultural, societal, and eco-
nomic factors operating in each environment. Further success can be anticipated in the
coming years as other research discoveries are translated into clinical practice, including
new approaches to treating intra-uterine infection, improvements in maternal nutrition,
and lifestyle modifications to ameliorate maternal stress. The widespread use of human
papillomavirus vaccination in girls and young women will decrease the need for surgical
interventions on the cervix and can be expected to further reduce the risk of early birth.
Together, this array of clinical interventions, each based on a substantial body of evidence,
is likely to reduce rates of preterm birth and prevent death and disability in large numbers
of children. The process begins with an acceptance that early birth is not an inevitable
and natural feature of human reproduction. Preventative strategies are now available and
need to be applied. The best outcomes may come from developing integrated strategies
designed specifically for each health-care environment.
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INTRODUCTION
Each year, 15 million babies are born preterm (1). Many may look
forward to a normal life, but others may die or live a life of disabil-
ity. Worldwide the rate of preterm birth is 11.1% but varies with
geography and race, ranging from 15% or more in some parts of
Africa to 5–6% in several European nations (2) and possibly lower
in some parts of East Asia (2).
In most countries, the rate of preterm birth has risen in recent
decades and worldwide now represents the largest cause of neona-
tal death (3) and the second largest direct cause of death in children
up to 5 years of age (2). Discovering how to lower the rate of this
major complication of pregnancy needs to be one of the highest
priorities in contemporary health care.
Prevention of early birth, however, presents several great chal-
lenges. The condition merely describes an event that occurs before
its due time, and is not a diagnosis in itself. There are many path-
ways leading to preterm birth and the prevention of each requires
different types of scientific inquiry and clinical strategies, which
together encompass a wide array of measurement systems and
clinical interventions across many health-care disciplines (4).
With such a great challenge, what evidence do we have that
prevention of preterm birth is possible and feasible?
LESSONS FROM POPULATIONS IN TRANSITION
Changing rates of preterm birth in populations in transition pro-
vide some evidence that environmental and lifestyle factors may
be involved, and these may be amenable to intervention.
In China, the rate of preterm birth is not known with cer-
tainty as there is no national obstetric data reporting system, but
the estimated rate is thought to be relatively low by international
standards. Hospital-based reports suggest rates ranging from 3 to
6% (5–8). A geographic-based study employing ultrasound con-
firmation of gestational age in early pregnancy in Jiangsu Province
indicated rates of 2.6 and 2.9% in urban and rural regions, respec-
tively (9). These rates appeared to rise as Chinese women lived in
increasingly Westernized environments, with preterm birth rates
of 4.4% in China-born women in Western Australia; 5.6% in non-
resident Chinese women living in Hong Kong; and 7.6% for Hong
Kong women with residency status. The factors underpinning
these differing rates suggest that environment and lifestyle may be
involved in modifying preterm birth rates and that factors oper-
ating outside traditional China may somehow have increased the
rate by several percentage points. These figures provide an indi-
rect clue as to the potential magnitude of the effect of preventative
strategies, at least in women of Chinese origin living in Western
environments.
Mexican women after migration to USA also experience an
increase in risk of preterm birth. Long-term immigrants who had
lived in USA for more than 5 years were shown to have a 1.9-
fold greater risk of delivering preterm, and a 1.5 greater risk of
giving birth to a low-birth weight infant when compared with
more recent arrivals (10). The factors involved in the increasing
preterm birth risks in these population groups are uncertain, but
long term Mexican immigrant women have been shown to have
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higher parity, more pregnancy complications, fewer planned preg-
nancies, and to smoke. An almost doubling in preterm birth rate
as these lifestyle factors are adopted by immigrant women suggests
that appropriate interventions may reduce the rate of early birth
by nearly half.
OPPORTUNITIES TO PREVENT PRETERM BIRTHS
“Green shoots” are now appearing in the field of preterm birth
prevention. At least in high-resource settings, some strategies are
suitable for immediate use in clinical practice, have a high likeli-
hood of success, and in many regions have already been adopted
in part or in whole. Other strategies have potential and feasibility,
but evidence for their effectiveness is still uncertain. Finally, there
are initiatives in place aimed at other clinical end-points but which
may incidentally prevent some cases of early birth.
The levels of evidence employed in this review and that enable
description of potential effectiveness in high-resource settings are
shown in Table 1, and the potential strategies that are feasible and
suitable for implementation are shown with their level of evidence
in Table 2.
STRATEGIES SUITABLE FOR IMMEDIATE USE
There are six strategies currently available with various levels of
evidence of effectiveness that are suitable for translation into clin-
ical practice in high-resource settings and have a high chance of
successfully preventing a proportion of preterm births.
PREVENTING NON-MEDICALLY INDICATED LATE PRETERM BIRTH
The most feasible approach to rapidly lowering the overall rate of
preterm birth is to address non-medically indicated late preterm
birth. Late preterm birth is defined as birth between 34 weeks
0 days and 36 weeks 6 days and these infants account for 70%
of all preterm births (18). In USA, the rate of preterm birth
increased by one-third over the last 25 years and this increase has
resulted almost entirely from a rise in late preterm births (19).
In the period 1990–2006, the late preterm birth rate for single-
ton births increased 20% from 6.7 to 8.1%. Similar increases in
late preterm birth have been described in other countries during
this time period, including South America (20), France (21), and
Australia (22, 23).
Late preterm birth is a potential danger to the child. Infants
born in the late preterm period are physiologically and metaboli-
cally immature. Their brain mass is approximately 70% of that of
a term infant and the ongoing process of myelination is reduced
accordingly (24). In the neonatal period, late preterm infants are at
increased risks of death, admission to neonatal intensive care, res-
piratory distress and need for mechanical ventilation (25), apnea,
temperature instability, hypoglycemia, hyperbilirubinemia, poor
feeding, separation from their mother, and re-admission after dis-
charge (24). In childhood, late preterm infants are at increased
risk of death (18), cerebral palsy (26), speech disorders (27),
growth delay and stunting (28), developmental delay (29), behav-
ioral problems including attention deficit disorder (24, 30, 31)
and learning difficulties (31, 32). The financial costs are consid-
erable, not just for the health-care system in the short term, but
for the individual, the family, and the society in terms of life-long
productivity.
Table 1 | Levels of evidence for intervention studies as used by the
Australian National Health and Medical Research Council (NHMRC)
and employed in this review.
Level Intervention
I Systematic review of level II studies
II Randomized controlled trial
III-1 Pseudo-randomized controlled trial (i.e., alternate allocation or
some other method)
III-2 Comparative study with concurrent controls
Non-randomized experimental trial
Cohort study
Case-control study
Interrupted time series with control group
III-3 Comparative study without concurrent controls
Historical control study
Two or more single-arm study
Interrupted time series without a parallel control group
IV Case series with either post-test or pre-test/post-test outcomes
https:// www.nhmrc.gov.au/ _files_nhmrc/ file/ guidelines/ developers/ nhmrc_
levels_grades_evidence_120423.pdf
Table 2 | Strategies to prevent preterm birth feasible for
implementation and likely to be successful in high-resource settings.
Strategy Possible reduction
in PTB
Level of
evidence
Prevent non-medically indicated late
preterm/early term birth
55% (11) III-3
Progesterone supplementation 45% (12) I
Cervical cerclage 20% (13) III-1
Tobacco control
Prevent smoking in pregnancy 20% (14) III-2
Smoke-free legislation 10% (15) III-3
Judicious use of fertility treatments 63% (16) I
Dedicated preterm birth prevention
clinics
13% (17) III-2
Levels of evidence as defined inTable 1.
Recently, the effect of birth in the early term period has received
increasing attention (33). Early term birth has been defined as
birth between 37 weeks 0 days and 38 weeks 6 days gestation (24)
and accounts for approximately 17% of all births. Rates of early
term birth have risen in recent years in many regions. Neona-
tal and infant morbidities are increased in the early term period,
when compared with births at 39 weeks gestation or more, but the
magnitude of excess risk is less than in the late preterm birth age
group. As an example, a recent Canadian study observed that the
adjusted relative risk for admission to neonatal intensive care was
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6.14 (95% CI 5.63, 7.03) for late preterm birth and 1.54 (95% CI
1.41, 1.68) for early term birth (34). For neonatal respiratory mor-
bidity, the adjusted relative risks were 6.16 (95% CI 5.39, 7.03)
and 1.46 (95% CI 1.29, 1.65), respectively. In a comparison of
outcomes after planned Cesarean section in 19 centers in USA,
it was observed that when compared with births at 39 completed
weeks, rates of admission to a neonatal intensive-care unit (NICU),
need for mechanical ventilation, and treatment for sepsis or hypo-
glycemia were increased 1.8- to 4.2-fold for births at 37 weeks and
1.3–2.1 for births at 38 weeks (35).
A significant proportion of all late preterm and early term
births result from obstetric or medical complications of pregnancy,
while others may be precipitated out of concern for maternal or
fetal well being. As a result, assessment of outcomes after birth is
confounded by the relative contributions of prematurity and any
abnormalities in the pregnancy that contributed to the early ges-
tational age at birth. The role of such biological determinants has
been investigated and found to be amplified at earlier gestational
ages, but quantification of the true relative contributions of ges-
tational age and biological determinants remain challenging and
will require further investigation (34).
Strategies addressing the increase in late preterm and early term
births will be enhanced by an understanding of the demographic
characteristics of those most at-risk. In a review of the factors
contributing to the rise in preterm birth rates at 36 and 37 weeks
gestation in USA between 1992 and 2002, non-Hispanic white
births were found to be the greatest contributor (36). Rates of
early preterm birth in Hispanic and black births remained rela-
tively constant. The factors underpinning the rise in non-Hispanic
white early births is likely to be socioeconomic and include access
to health care and possibly maternal request for intervention.
If then the major contributor to rising preterm birth rates in
recent years has been late preterm birth, is it possible to intervene
and can it be done with safety? The clinical reasoning behind many
cases of early intervention is to prevent stillbirth. In a 10-year
population-based study in New South Wales, Australia encom-
passing more than 100 hospitals and approximately one-third of
all births in Australia, the number of planned interventions before
the estimated due date was found to have increased to 26% of
all singleton births >32 weeks gestation (22). Stillbirth rates were
unchanged over this time period, indicating that at least at a pop-
ulation level, the increased intervention did not improve infant
survival.
Researchers in Denmark have reported the outcomes of the first
randomized controlled trial of elective Cesarean section planned
for 38 weeks, versus 39 weeks, gestation (37). An original sample
size of 1010 participants was increased to 1270 when a high rate
of non-compliance was observed. There were small reductions in
rates of admission to NICU in the delayed delivery group, but the
differences were not statistically significant. Interpretation of these
findings is confounded by uncertainty as to whether the study was
under-powered and by the unexpected high rate of earlier delivery
in the planned later birth group (23).
The effects of introducing policies to lower the rate of elective
delivery before 39 weeks gestation have been reported as a ret-
rospective cohort of prospectively collected data (11). The study
involved 27 facilities across 14 states in USA. After an education
campaign and declaration of an intent to reduce non-medically
indicated birth <39 weeks gestation on the basis of patient safety,
medical staff were allowed to choose one of three approaches: (1) a
“hard stop” approach in which elective delivery <39 weeks would
be refused by hospital staff and the policy would be enforced;
(2) a “soft stop” approach in which compliance would be left to
individual clinicians but that any departure from policy would
be referred to a local peer review committee for “evaluation and
potential action”; and (3) an “education only” approach.
During the study period, the rate of elective delivery between
37 and 39 weeks gestation fell significantly from 9.5% of all births
in 2007 to 4.3% of births in 2009. The rate of elective early term
delivery was significantly reduced in both the “hard stop” and
“soft stop” groups, and the reduction in the “hard stop” group was
double that in the “soft stop” group. There was a small decline
in the “education only” group, but the difference did not achieve
statistical significance. Interestingly, there was considerable varia-
tion between facilities in their rates of elective delivery<39 weeks
before the intervention commenced. Each facility had self-selected
their choice of the three strategies. The large reduction in rates
of early birth in some facilities, which began with high levels of
intervention indicates that any such intervention may be most
effectively targeted at those with the highest rate of early interven-
tion. Overall, in the study facilities during the observation period,
the rate of term newborn intensive care admission fell 15% from
8.9 to 7.5% (CI 0.79, 0.92), while stillbirths rates were unchanged.
The findings of this intervention cohort study provide strong
evidence that the rate of late preterm and early term birth may be
lowered and result in a 15% reduction in admissions to neonatal
intensive care. Such an approach does not appear to increase the
rate of stillbirth. Education alone did not significantly improve
outcomes, but the process of education was aimed solely at the
health-care providers, and it is yet to be seen if a combined
approach of providing education to both the women themselves
and the health-care personnel may result in a more favorable
outcome.
The price for obstetricians and their hospitals of delaying birth,
however, is an increase in the number of births out-of-hours. In
a secondary analysis of the Danish randomized controlled trial of
planned Cesarean birth at 38 or 39 weeks gestation (38), planned
delivery at 39 weeks compared with 38 weeks resulted in a 60%
increase in unscheduled Cesarean sections and a 70% increase
in deliveries outside regular working hours. Further research is
urgently required to determine the most effective strategies by
which late preterm and early term births may be minimized
without deleterious impacts on the health-care system and while
maintaining patient safety. Future strategies may be most effective
if they recruit to the cause not just the health-care professionals
but also the pregnant women and their families.
PROGESTERONE SUPPLEMENTATION
For several decades, there has been interest in the potential use
of progesterone supplementation to prevent preterm birth but a
series of recent studies has now provided strong evidence for their
usefulness.
Ironically, the mechanism by which progesterone may delay
birth remains uncertain. In non-primate placental mammals, the
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uterine quiescence of pregnancy is maintained by high circulat-
ing levels of progesterone and falling levels herald the onset of
labor (39). In human beings, there is no such decline in circulat-
ing levels before labor (40). Two possible mechanisms of action
are proposed. First, progesterone has an anti-inflammatory action
that may counteract the inflammatory process that is involved in
initiation of labor (41). Second is a possible functional withdrawal
of progesterone through changes in progesterone receptors and
their transcriptional activity at a tissue level (41–43).
Progesterone has been administered in several formulations.
For preterm birth prevention, natural progesterone is used (44).
Synthetic progesterones, such as medroxyprogesterone acetate are
not used as they have significant androgenic activity. Natural prog-
esterones can be given vaginally, orally, or by injection. Vaginal
progesterone has the advantage of being locally available and has
few side effects although some women complain of vaginal irri-
tation. The half-life is 13 h (45) and daily treatment is required.
Various doses are employed ranging from 90 to 400 mg but there
is no evidence that any one dose is superior to another. An alterna-
tive agent is 17 α-hydroxy-progesterone (17P) caproate, which is
also a natural progesterone conjugate but with a longer half-life of
7 days (44). 17P is administered intramuscularly and is given once
each week. Both these progesterone formulations are considered
to be safe in pregnancy.
In women with a past history of preterm birth, progesterone
has been shown in meta-analysis of RCTs to significantly reduce
the risk of preterm birth <34 weeks (RR 0.31 95% CI 0.14–0.69),
preterm birth <37 weeks (RR 0.55, 95% CI 0.42–0.74), perinatal
death (RR 0.50, 95% CI 0.33–0.75), need for assisted ventilation
(RR 0.40, 95% CI 0.18–0.90), necrotizing enterocolitis (RR 0.30,
95% CI 0.10–0.89), and admission to neonatal intensive care (RR
0.24, 95% CI 0.14–0.40) (46).When given to women with a past
history of preterm birth, there is no evidence for a difference
in effectiveness between daily natural vaginal progesterone and
weekly intramuscular 17P injections. As a result of these findings,
the American College of Obstetricians and Gynecologists recom-
mends that “progesterone supplementation for the prevention of
recurrent preterm birth should be offered to women with a sin-
gleton pregnancy and a prior spontaneous preterm birth due to
spontaneous labor or premature rupture of membranes” (47).
There is also strong evidence that progesterone treatment may
prevent preterm birth in women shown to have a short cervix on
ultrasound imaging in mid-pregnancy. Meta-analysis of individ-
ual patient data of five trials has shown that vaginal progesterone
given to pregnant women in the mid-trimester with a short cervix
(≤25 mm) is associated with a significant reduction in the rate of
preterm birth<28 weeks (RR 0.50, 95% CI 0.30–0.81),<33 weeks
(RR 0.58, 95% CI 0.42–0.80) and <35 weeks (RR 0.69, 95% CI
0.55–0.88), in addition to significant reductions in risk of new-
born complications including respiratory distress syndrome, need
for mechanical ventilation, admission to neonatal intensive care,
and composite morbidity and mortality (48).
If progesterone is so effective in preventing preterm birth in
women with a short cervix in mid-pregnancy, should all preg-
nant women be screened for cervical length at this time? The
question is of great importance and remains controversial. In one
of the major and most important trials in this field, Hassan and
colleagues allocated at random asymptomatic women with a sin-
gleton pregnancy and short cervix (10–20 mm) between 19 weeks
0 days and 23 weeks 6 days to receive either vaginal progesterone
gel or placebo daily (12). Preterm birth and the major compli-
cations of prematurity were halved by the treatment, consistent
with the findings from other studies. The numbers of women,
however, required to achieve this reduction were large. A total of
32,091 pregnant women were screened to identify 733 with a cervix
length between 10 and 20 mm. 268 women declined to participate
or were excluded, leaving 236 randomized to the treatment group
and 229 to the placebo. The primary outcome of birth <33 weeks
was observed in 21 cases in the treatment group (8.9%) and 36
cases in the placebo group (16.1%), preventing the early birth of
15 cases out of 36 eligible. Therefore, if we were to assume that
introduction into clinical practice were to involve administration
of vaginal progesterone to all women with a cervix between 10
and 20 mm in mid-pregnancy, and replacing the use of placebo
with active treatment and avoiding the refusal to participate of
the approximately one-third of eligible women observed in the
research study, then screening 32 thousand asymptomatic preg-
nancies would identify 733 suitable women (2.3%) resulting in
prevention of birth <33 weeks in 47 cases (14.7 per 10,000).
There is no doubt that any clinical strategy that would prevent
the preterm birth of so many infants would be of considerable
benefit to our patients and their families. The cost-effectiveness,
however, would be dependent on the health-care environment and
availability of appropriate resources and funds. In a decision analy-
sis model comparing no routine cervical length screening with a
single routine ultrasound trans-vaginal cervical length measure-
ment at 18–24 weeks gestation, with the women with a short cervix
then offered vaginal progesterone treatment, the policy appeared
to be cost effective (49). In US dollars in the year 2010, for every
100,000 women screened, $12 million could be saved and 424
quality-adjusted life-years gained.
At this time, the American College of Obstetricians and Gyne-
cologists has not recommended routine cervical length screening
for all pregnancies,probably as a result of the large numbers requir-
ing to be screened, and a perceived need for further studies to be
conducted across a variety of health-care settings (47, 50). Practice
guidelines are required in each clinical environment that enable the
effectiveness of this protocol to be adopted within the resources
and expertise that can be harnessed for the challenge. As our use
of progesterone expands, we also need to remain mindful that we
do not yet have data describing the complete safety of their use for
later child and adult life.
Progesterone has also been evaluated as a potential treatment in
other conditions that may lead to preterm birth. Studies conducted
to-date have shown that progesterone treatment is not effective in
preventing preterm birth in multiple pregnancies, preterm labor,
or preterm pre-labor rupture of membranes (46, 47).
CERVICAL CERCLAGE
Cervical cerclage is the surgical placement of a suture or tape
around the cervix in an attempt to prevent dilatation and
subsequent preterm birth. The procedure was first described by
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Shirodkar in 1955 and involved dissection of the bladder superi-
orly to enable placement of the suture as close to the internal os as
possible (51). A simplified procedure was described by McDonald
2 years later in which bladder dissection is not performed, mini-
mizing the intervention but possibly leaving the suture lower in
the cervix (52).
The decision to insert a cervical cerclage in mid-pregnancy is
based on one of the three scenarios. First, a history of preterm
births, classically recurrent and painless second trimester losses.
Second, shortening of the cervix on ultrasound imaging. Third,
short or dilated cervix on physical examination (13).
The mechanistic basis by which cerclage is effective is simplis-
tically described as physical closure of the cervix, but the concept
of cervical “incompetence” remains as much an enigma today as
it was when described by Shirodkar in 1955 (51). As a result, the
benefits of the procedure need to be carefully balanced against
the potential risks and alternative therapies. The effects of cerclage
on the cervico-vaginal microbiota may be clinically important,
although has not yet been investigated.
Cerclage compared with no treatment
Meta-analysis of the RCTs that have compared cervical cerclage
against no treatment has shown a significant reduction in preterm
births of 20% (average RR 0.80, 95% CI 0.69–0.95) and with a
reduction in perinatal deaths although this difference did not
quite reach statistical significance (RR 0.78; 95% CI 0.61–1.00)
(13). However, cerclage was associated with higher rates of fever,
vaginal discharge, and vaginal bleeding, together with a signifi-
cant increase in delivery by Cesarean section (RR 1.19, 95% CI
1.01–1.40).
Cerclage compared with progesterone
Only one trial has attempted to directly compare ultrasound-
indicated cervical cerclage with a progesterone (53). The prog-
esterone was 17P given intramuscularly. The trial was halted pre-
maturely, and the sample size was too small to make meaningful
conclusions (13).
No trial has compared vaginal progesterone versus cerclage for
ultrasound-detected cervical shortening in mid-pregnancy (13).
An indirect comparison using adjusted indirect meta-analysis of
trials was reported by Conde-Agudelo et al. (54). The analysis
included trials of singleton pregnancies with a history of previous
preterm birth and in which ultrasound imaging had demonstrated
a short cervix in mid-pregnancy. Both vaginal progesterone and
cerclage were found to be effective in preventing preterm birth
and improving perinatal outcomes. Neither treatment, however,
was superior to the other.
At this time, the evidence guiding clinical practice in making a
decision to insert a cervical cerclage versus administration of prog-
esterone is incomplete. Decisions need to be based on informed
consent and include patient and clinician preference, as well as the
local availability of surgical resources and expertise.
Cerclage compared with pessary
Cervical pessaries have been proposed as an alternative method of
preventing preterm birth (55). A range of designs has been pro-
posed and some success has been described. At this time, however,
the role of pessaries and the most effective clinical protocols for
their use remain under investigation.
PREVENT CIGARETTE SMOKING
Tobacco smoking in pregnancy causes preterm birth in addition
to a dose-dependent reduction in birthweight (14, 56, 57). The
exact mechanism by which preterm birth is triggered is uncertain
and probably relates to the vasoconstrictive effects of nicotine,
the increase in circulating levels of carbon monoxide, or other as
yet unknown effects from the 4000 chemically active components
in tobacco smoke. The woman herself does not need to be the
smoker for there to be an increased risk of preterm birth. Second-
hand smoke is associated with an increased risk of early birth,
as well as stillbirth, low birthweight, and respiratory disorders in
childhood (58).
The nicotine in cigarette smoke is addictive and produces the
positive feelings inherent in addictive behaviors. Strategies aim-
ing to prevent smoking in pregnancy, however, are complicated by
the many factors that contribute to the decision-making processes
in women who elect to smoke while pregnant. In high-income
countries, rates of smoking in pregnancy have declined in recent
years but the reduction has not been in all groups (59, 60). Smok-
ing in pregnancy in high-income countries is now a marker of
social disadvantage and remains common in many indigenous
groups (61). There are also cultural factors that contribute, result-
ing in complex interplays between socio-economic disadvantage,
social isolation,cultural background,migration,and mental health
(62–64). Hence, anti-smoking campaigns that are effective in one
demographic group may alienate others and be either ineffective
or even be at-risk of producing an opposite effect.
Nevertheless, the risk of preterm birth attributable to smoking
has been estimated as more than 25% and reducing smoking rates
in pregnant women must be of highest priority (65). Psychosocial
interventions appear to be moderately effective. Pooled data from
14 studies describing a variety of psychosocial interventions have
shown a significant reduction in smoking rates (RR 0.82, 95% CI
0.70–0.96) (64). The number need to treat to prevent one case of
preterm birth was 71.
Pharmacological interventions may be of less value. Nicotine
replacement therapy is the only pharmacotherapy for smoking ces-
sation in pregnancy that has been adequately tested. A review of
the six published trials was unable to confirm benefit (66). Further
studies involving different demographic groups and alternative
agents are required.
In contrast, smoke-free legislation appears to be of great ben-
efit (15). A review of 11 studies involving local or national bans
and including more than 2.5 million births showed that smoke-
free legislation was associated with a significant 10% reduction in
preterm births (95% CI −18.8 to −2.0). The data in this analysis
were observational rather than randomized, but the likelihood of
causality was increased by the dose-dependent nature of the effect
with comprehensive smoking laws appearing to produce the great-
est benefit. It is likely that the major action on pregnancy outcomes
from the legislative changes resulted from reductions in second-
hand smoke effects. It is of interest that the reduction in preterm
birth rates was not associated with a similar effect on rates of low
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birthweight. Maternal smoking in pregnancy is known to produce
a dose-dependent reduction in birthweight, and it is possible that
second-hand smoke exposure may act to trigger preterm birth
acting through a more rapid and different pathway to chronic
exposure to cigarette smoke where there is a most definite and
consistent effect on fetal growth.
JUDICIOUS USE OF FERTILITY TREATMENTS
The advent of fertility assistance has contributed to a significant
increase in the rate of preterm birth. Central to this contribution
has been an increase in the incidence of multiple pregnancies. In
USA, the incidence of multiple births has doubled from 1.8% of all
births in 1972 to 3.5% in 2011 (67), and this rise can be attributed
to an increase in the use of medically assisted reproduction. It has
been estimated that in the US in 2011, 36% of twin births and 77%
of triplet and higher order multiple births were due to medically
assisted conception (67).
Data on in vitro fertilization (IVF) cycles in many countries are
relatively easy to analyze; however, the data capture on less invasive
treatments, such as ovulation induction and intra-uterine insem-
ination cycles (often combined with ovarian stimulation) are less
readily available. These treatments often involve ovarian stimula-
tion and clinicians and patients may elect to proceed to fertility
treatment when several follicles are potentially available for ovu-
lation. In such circumstances, multiple pregnancies may result.
In 2000, the incidence of twin gestations resulting from non-IVF
fertility treatment was estimated to be 20% (68).
The risk of preterm birth that may result from fertility treat-
ment can best be addressed by education of the attending health-
care practitioners. The rate of multiple gestations resulting from
IVF treatment can be reduced to relatively low levels. In Aus-
tralia and New Zealand, single embryo transfer has been embraced
widely resulting in a multiple pregnancy rate following IVF of only
6.9% (69). Transferring a single embryo minimizes the risk of mul-
tiple pregnancy but requires an environment of high competence
and patient education as the overall pregnancy rate is less (16). In
recent years, the percentage of embryo transfers that were single in
Australia and New Zealand was 69%, compared to 40% in the UK
(www.HFEA.gov.uk). Meanwhile, in USA, the percentage of single
embryo transfers was 21%, resulting in IVF being responsible for
one in five multiple births in that country in 2011 (67).
Currently, one in 25 children born in Australia has resulted
from IVF procedures (70). In Denmark, the percentage is almost
5% (70). As the use of IVF technology spreads progressively across
the world, measures are required to ensure that responsible ovu-
lation induction treatment and a single embryo transfer approach
in IVF treatment are embraced to minimize the risk of multiple
pregnancies and risk of preterm birth.
Multiple pregnancies are not the only pathway by which fertility
treatment can lead to preterm birth. It is well established that there
are other obstetric and perinatal complications that may befall a
mother and her infant as a result of IVF treatment (71, 72). At
first, it was thought that additional perinatal risks resulted purely
from complications of multiple pregnancies but data from several
countries in which single embryo transfer is common have shown
additional risks even in the presence of a single fetus. The causes
of these additional risks are unclear. One contributing factor may
be the underlying cause of the subfertility. Evidence for an effect
of subfertility itself has come from observations that women with
a history of subfertility who conceive spontaneously have a signif-
icantly worse perinatal prognosis than those with normal fertility
(73–75), and women who require intra-uterine insemination have
a significantly worse perinatal outcome than women who sponta-
neously conceive (74, 76). Ironically, some of the worst perinatal
outcomes exist for women who conceive a singleton pregnancy
as a result of IVF treatment, with an approximate doubling of the
risk of stillbirth, growth restriction, preterm delivery, and neonatal
nursery admission for their baby (71, 72, 77, 78). Hence, a woman
with subfertility has an increased perinatal risk due to her subfer-
tility. Further, the perinatal mortality of a single fetus conceived
after a double embryo transfer procedure is significantly greater
than a singleton conceived from a single embryo transfer (79).
Despite the trend toward single embryo transfer, the incidence
of monozygotic twinning is believed to remain increased by IVF
treatment by an additional 1–5% (80). The risk of monozygotic
twinning is particularly increased by the procedures of assisted
hatching (81) and blastocyst transfer in comparison to early
embryo transfer (82). As a result, these procedures increase the
risk of preterm birth.
Finally, children born as a result of assisted reproductive tech-
nology have an excess risk of birth defects when compared to
spontaneously conceived children, further increasing the chance
of obstetric intervention and preterm birth (83).
DEDICATED PRETERM BIRTH PREVENTION CLINICS
In recent years, many health regions and hospitals have developed
dedicated preterm birth prevention clinics. These clinics and their
associated services have employed a wide variety of criteria outlin-
ing who should attend and the protocols for management. The first
large-scale attempt to determine the effectiveness of such a pro-
gram was the West Los Angeles Preterm Birth Prevention Project
in which eight prenatal county clinics in California were allocated
at random to be experimental or control clinics (84). The interven-
tion was based on providing additional education to the women
and offering more clinic attendances. In the experimental group,
there was a 19% reduction (9.1–7.4%) in the preterm birth rate
when compared with that of the control clinics. This difference in
rates was statistically significant when the number of patient risk
factors was taken into account. In pregnancies of black women, the
preterm birth rate was 15% in the experimental clinics and 22%
in the control clinics. Secondary interventions of bed rest, social
work assistance, and oral synthetic progesterone medication were
of no additional benefit.
More recently, most dedicated preterm birth prevention clinics
have focused on newer diagnostics and therapeutic interventions
including assessment of vaginal microbiology, fibronectin testing,
ultrasound detection of shortened cervix, antibiotic use, proges-
terone therapy, cervical cerclage, and Arabin cervical pessaries. A
survey of 23 dedicated preterm birth prevention clinics in UK
in 2012/13 revealed considerable heterogeneity in protocols and
practices suggesting a need for effective networking and coordina-
tion of such services (85). Also, there was considerable variation
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in the criteria for referral and attendance, reflecting the fact that
risk scoring systems have generally been unhelpful in predicting
preterm birth (86). Most clinics attempt to target women with a
history of preterm birth or recurrent mid-pregnancy loss, previ-
ous preterm pre-labor rupture of membranes, or previous loop
excision or cone biopsy of the cervix (85).
Using a retrospective cohort design, investigators from Utah,
USA reported a significant reduction in recurrent preterm birth
(48.6 versus 63.4%) in women who attended a dedicated clinic
and with lower rates of composite major neonatal morbidity
(5.7 versus 16.3%) (87). The intervention was consultative and
consisted of three standardized clinic attendances with routine
prescription of 17-alpha hydroxyprogesterone caproate, as well as
sonographic measurement of cervical length. Using a similar study
design, investigators from Ohio, USA reported on the outcomes
from their preterm birth prevention clinic after adoption of an
accelerated appointment process and prophylactic treatment with
progesterone (88). After adjustment for major confounders, these
changes to their practice resulted in a significant 25% decrease in
spontaneous preterm birth.
Despite the relatively large number of preterm birth preven-
tion clinics now operating in various parts of the world, a review
of their effectiveness could identify only three trials that qualified
for inclusion in the analysis, and with only one study providing
outcome data on most end-points (17). When data from the three
trials were pooled, there were fewer preterm births in the treatment
group compared with controls, but the difference between groups
was not statistically significant (RR 0.87, 95% CI 0.69–1.08). The
authors concluded that adequate randomized controlled trials of
preterm birth prevention clinics may never be performed as such
clinics have become an accepted part of antenatal care in many
countries.
In addition to the enhanced provision of expert care and
application of effective interventions for at-risk women, an impor-
tant function of dedicated preterm birth prevention clinics may
also be to alleviate maternal anxiety. Stress has been thought for
many years to be a possible cause of some cases of early birth,
and research is needed on the potential benefits or otherwise of
attendance at such clinics (89).
STRATEGIES WITH PROMISE BUT REQUIRING MORE
RESEARCH
TREATMENT OF INTRA-UTERINE INFECTION
Intra-uterine infection and inflammation play a well-recognized
role in the etiology of spontaneous preterm labor, particularly in
deliveries less than 32 weeks gestation (90) or those complicated
by preterm pre-labor rupture of membranes (91). The primary
reservoir for such infection is the vagina. Vaginal microorgan-
isms are hypothesized to breach the cervical barrier, colonize the
fetal membranes, and eventually the amniotic cavity (91, 92).
The vigorous inflammatory response ultimately leads to preterm
birth.
The microorganisms most commonly isolated from the amni-
otic fluid are very small bacteria of the Class Mollicutes, namely
Ureaplasma and Mycoplasma species (93). Numerous other
bacteria have also been identified in infected amniotic fluid sam-
ples including Streptococcus, Fusobacterium, and Enterobateriaceae.
The frequent presence of these organisms does not necessarily
denote causation, but there is evidence from several sources to
support a role for some of these organisms in the causal pathway
to preterm labor. In experimental sheep, intra-amniotic injection
of Ureaplasma spp. elicits a robust intra-uterine inflammatory
response and enhanced lung maturation (94–96). Intra-amniotic
injection with Ureaplasma spp. in chronically catheterized Rhe-
sus macaques drives intra-uterine cytokine and prostaglandin
production, chorioamnionitis and preterm labor, replicating the
disease pathogenesis and ontogeny observed in human preg-
nancy (97).
The relationships between vaginal microbiota and ascending
infection resulting in preterm birth remain uncertain. For several
decades, investigators have explored a role for bacterial vaginosis.
Bacterial vaginosis is a common genital condition among women
of reproductive age characterized by a disturbance in normal vagi-
nal microbiota with a loss of H2O2-producing Lactobacillus spp.,
an increase in vaginal pH, and an increase in Gram-variable cocco-
bacilli, anaerobic organisms, and genital mycoplasmas (98). There
are well-established associations between bacterial vaginosis and
preterm birth (99), but the extent of a causative role is not certain.
What is known with certainty, however, is that bacterial vaginosis
varies dramatically with race and that studies need to be specific
for different population groups (98, 100).
Antibiotic treatment of bacterial vaginosis is generally ineffec-
tive in preventing preterm birth (101–103). It should be noted,
however, that antibiotics commonly used to treat bacterial vagi-
nosis are ineffective against Ureaplasma and Mycoplasma spp.,
which are the organisms most frequently associated with preterm
birth. These organisms are best treated with macrolide antibi-
otics, the most frequently used of which are erythromycin and
azithromycin. In addition, the transplacental passage of these
drugs is poor and unlikely to reach levels sufficient to erad-
icate infection (104–107). Newer macrolide antibiotics, such
as solithromycin, with greater efficacy and better transplacen-
tal passage, offer promise and may prove in time to be more
effective (108, 109).
There is some evidence, however, that treatment earlier in preg-
nancy may be more effective in preventing preterm birth. Lamont
and colleagues have shown that administration of clindamycin to
women with abnormal vaginal flora before 22 weeks gestation may
reduce the rate of subsequent preterm birth (110). This possibil-
ity is the topic of a separate review in this series where it will be
discussed at length.
In summary,while a role for vaginal infection in the causal path-
way to many cases of early preterm birth seems clear, at this time
translation of that knowledge into an effective treatment strategy
has yet to be widely adopted. The field is the subject of active
investigation and progress can be anticipated in the near future.
NUTRITIONAL INTERVENTIONS
There has been considerable research on the interactions between
nutrition and risk of preterm birth, but the many environments
and demographic groups included in these studies complicates
interpretation. A low pre-pregnancy body mass index (BMI) has
been associated with an increased risk of preterm birth, while
obesity has been shown to be protective (111). Obesity, however,
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predisposes pregnant women to diabetes and pre-eclampsia often
leading to iatrogenic early birth.
It has been known for many years that there are associations
between preterm birth and low serum levels of many micronutri-
ents. Proving a causative role and using supplementation to reduce
preterm birth rates has, however, so far remained elusive.
In a large cohort study, a strong association was observed
between use of pre-conception folate supplementation for one year
or more and reduction in risk of preterm birth before 32 weeks
gestation, but not at later gestational ages (112). However, the
randomized controlled trials designed to investigate the effects of
peri-conception folate supplementation on rates of neural tube
defects did not reveal any reductions in rates of miscarriage or low
birthweight (113). It is entirely possible that observational studies
of folate use may describe a population of women at lower risk
of preterm birth for other reasons. Further research is required
before peri-conception folate supplementation can be considered
to be an effective strategy to prevent preterm birth.
Research is underway investigating the possibility that mater-
nal intake of omega-3 long-chain polyunsaturated fatty acids may
prevent preterm birth and improve birth weight. The impetus
for this hypothesis was the observation that women living in the
Faroe Islands who have a high consumption of fish oil also have
pregnancies of longer gestational ages and infants of high birth
weight (114). A recent randomized controlled trial using the n – 3
(omega-3) long-chain polyunsaturated fatty acid docosahexaenoic
acid (DHA) in the last half of pregnancy resulted in fewer preterm
births before 34 weeks gestation, longer gestations and shorter hos-
pital stay for preterm infants (115). Such results are encouraging
but further research is required before supplementing the mater-
nal diet with omega-3 fatty acids to prevent preterm birth can be
recommended (116).
AMELIORATION OF MATERNAL STRESS
It has been shown that women with high levels of psychological
or social stress are at increased risk of preterm birth (117–119).
Randomized controlled trials of interventions aiming to relieve
stress or provide comforting reassurance have not been successful
in preventing early birth suggesting that multiple other confound-
ing factors are contributing to the relationship between stress and
preterm birth (120).
TREATMENT OF PERIODONTAL DISEASE
It has been known for many years that periodontal disease is associ-
ated with preterm birth (121). Inflamed and infected periodontal
tissues could stimulate preterm labor either by translocation of
periodontopathic organisms, or by stimulation and release of
inflammatory mediators and prostaglandins into the maternal
circulation (122). Disappointingly, randomized controlled trials
of treating periodontal disease during pregnancy have failed to
lower the rate of preterm birth (123–125). It seems likely that the
alterations in maternal immune responses that cause periodontal
disease also predispose women to preterm birth, but that treating
periodontal disease during pregnancy will neither cause nor pre-
vent this major complication of pregnancy. Nevertheless, further
research is required to investigate if there is any benefit in reducing
rates of preterm birth by treatment of periodontal disease before
conception as the randomized controlled trials conducted so far
have initiated treatment in mid-pregnancy.
PREVENTION OF SURGICAL TREATMENT FOR CERVICAL
INTRA-EPITHELIAL NEOPLASIA
It is well established that surgical treatments of cervical intra-
epithelial neoplasia (CIN) predispose women to preterm birth in
subsequent pregnancies, including early preterm birth (126). Such
treatments aim to prevent cancer of the cervix and the possible
risks for future pregnancies have always been judged against the
need to prevent life-threatening cancer. It has now been shown
that the vast majority of cases of CIN are caused by human papil-
lomavirus (HPV) infection (127). The discovery and introduction
of a vaccine to prevent HPV infection can now be expected to
dramatically reduce the prevalence of pre-invasive abnormalities
of the cervix and hence decrease the need for surgical treatments
that may predispose women to subsequent preterm births (128).
In addition to saving lives of young women who are vaccinated, it
is likely that time will show that discovery of the vaccine to pre-
vent HPV infection will have serendipitously improved outcomes
for the next generation by also preventing early birth. Population-
based vaccination of young women to prevent HPV vaccination
needs to be given high priority.
CONCLUSION
In recent decades, advances in newborn care have resulted in
improved outcomes for large numbers of children who have been
born too early but this progress has not been matched by simi-
lar advances in our ability to prevent preterm birth. Times have
changed. We now have increasing evidence that a variety of inter-
ventions have potential to significantly and safely prevent a mean-
ingful proportion of preterm births. Translation of recent discov-
eries into clinical practice will have different requirements for high
and low-resource settings, and for different population groups.
For each setting, the best chance of success will come from an
integrated implementation strategy that harnesses both the health-
care personnel and the pregnant women for whom they provide
care. The interventions are in many cases multi-disciplinary and
require the participation of personnel from multiple fields includ-
ing those who make local and national policies. This process begins
with awareness across the medical and general communities that
preterm birth is one of modern health care’s greatest challenges,
but that prevention in many cases is now possible.
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